{
    "clinical_study": {
        "@rank": "82223", 
        "acronym": "COMMAND-Asia", 
        "arm_group": [
            {
                "arm_group_label": "pegIFN\u03b1 2a + Ribavirin + Placebo", 
                "arm_group_type": "Experimental", 
                "description": "pegIFN\u03b1 2a 180 \u00b5g, Solution for injection, Subcutaneous, Once weekly, 48 weeks\nRibavirin 200 mg Tablets, by mouth, 400-600mg AM,  600 mg PM, 48 weeks\nPlacebo 0 mg Tablets, by mouth, Once daily, 24 weeks"
            }, 
            {
                "arm_group_label": "pegIFN\u03b1 2a + Ribavirin + Daclatasvir", 
                "arm_group_type": "Experimental", 
                "description": "pegIFN\u03b1 2a 180 \u00b5g, Solution for injection, Subcutaneous, Once weekly, 24 or 48 weeks depending on response\nRibavirin 1000-1200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 24 or 48 weeks depending on response\nDaclatasvir 60 mg Tablets, by mouth, Once daily, 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether 24 week treatment with the Daclatasvir\n      (DCV) in combination with Pegylated-interferon alfa 2a (pegIFN\u03b1-2a) and Ribavirin (RBV) is\n      safe and demonstrates rate of Sustained Virologic Response at follow up week 24 (SVR24)\n      (defined as undetectable HCV RNA at post-treatment Week 24) that are non-inferior to 48\n      weeks of the dual combination therapy of pegIFN\u03b1-2a/RBV in a majority of study subjects"
        }, 
        "brief_title": "Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment na\u00efve Patients", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients chronically infected with Hepatitis C virus (HCV) GT 1 or 4\n\n          -  HCV RNA viral load \u2265 10,000 IU/mL\n\n          -  Na\u00efve to prior treatment with any interferon formulation, Ribavirin (RBV) or HCV\n             direct antiviral agent\n\n          -  Patients with compensated cirrhosis are permitted\n\n        Exclusion Criteria:\n\n          -  Infected with HCV other than GT 1 or 4\n\n          -  Evidence of decompensated liver disease\n\n          -  Documented or suspected Hepatocellular carcinoma (HCC) as evidenced by previously\n             obtained imaging studies or liver biopsy\n\n          -  Evidence of a medical condition contributing to chronic liver disease other than HCV\n\n          -  History of chronic Hepatitis B virus (HBV) or Human immunodeficiency virus (HIV)\n\n          -  Current or know history of cancer (except in situ carcinoma of cervix or adequately\n             treated basal or squamous cell carcinoma of the skin) within 5 years prior to\n             enrollment\n\n          -  Laboratory values:\n\n               1. Hemoglobin < 12 g/dL (females) or < 13 g/dL (males)\n\n               2. Platelets < 90 x 1000000000 cells/L\n\n               3. Absolute neutrophil count (ANC) < 1.5 \u00d7 1000000000 cells/L\n\n               4. Total bilirubin \u2265 34 \u00b5mol/L (unless due to Gilbert's disease)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797848", 
            "org_study_id": "AI444-047"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "pegIFN\u03b1 2a + Ribavirin + Placebo", 
                    "pegIFN\u03b1 2a + Ribavirin + Daclatasvir"
                ], 
                "intervention_name": "Peginterferon alfa 2a", 
                "intervention_type": "Drug", 
                "other_name": "Pegasys\u00ae"
            }, 
            {
                "arm_group_label": [
                    "pegIFN\u03b1 2a + Ribavirin + Placebo", 
                    "pegIFN\u03b1 2a + Ribavirin + Daclatasvir"
                ], 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Copegus\u00ae (Taiwan, Korea and Singapore)", 
                    "Wei Lining (China)"
                ]
            }, 
            {
                "arm_group_label": "pegIFN\u03b1 2a + Ribavirin + Placebo", 
                "intervention_name": "Placebo matching Daclatasvir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "pegIFN\u03b1 2a + Ribavirin + Daclatasvir", 
                "intervention_name": "Daclatasvir", 
                "intervention_type": "Drug", 
                "other_name": "BMS-790052-05"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Ribavirin", 
                "Peginterferon alfa-2a"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 21, 2013", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Randomized, Double Blind, Multi-National Evaluation of Daclatasvir in Combination With Peg Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotypes 1 and 4", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "China: Ethics Committee", 
                "Korea: Food and Drug Administration", 
                "Korea: Institutional Review Board", 
                "Singapore: Health Sciences Authority", 
                "Singapore: Clinical Trials & Epidemiology Research Unit (CTERU)", 
                "Singapore: Domain Specific Review Boards", 
                "Taiwan : Food and Drug Administration", 
                "Taiwan: Institutional Review Board", 
                "Taiwan: Research Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of Genotype 1 subjects with SVR24, defined as HCV RNA < Limit of quantification (LOQ) at follow-up Week 24 for each cohort", 
            "safety_issue": "No", 
            "time_frame": "Week 24 post treatment follow up"
        }, 
        "removed_countries": {
            "country": "Taiwan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797848"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Genotype (GT) 4 subjects with SVR24", 
                "safety_issue": "No", 
                "time_frame": "Week 24 post treatment follow up visit"
            }, 
            {
                "measure": "Proportion of GT 1 & 4 subjects who achieve HCV RNA < LOQ or undetectable", 
                "safety_issue": "No", 
                "time_frame": "Week 24 post treatment follow up visit and Week 48 post treatment follow up visit for subjects who achieve Virologic response [VR]  (4&12)"
            }, 
            {
                "measure": "Frequency of Serious Adverse Events (SAEs)/discontinuations due to Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 48 weeks plus 30 days"
            }, 
            {
                "measure": "Discontinuations due to Adverse Events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 weeks plus 7 days"
            }, 
            {
                "measure": "Proportion of subjects with Sustained Virologic Response at follow up week 12 (SVR12) or SVR24 by rs12979860 Single nucleotide polymorphism (SNP) in the IL28B gene", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 weeks"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}